Capricor Therapeutics Analyst Ratings
Capricor Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/04/2023 | 1370.59% | HC Wainwright & Co. | $18 → $40 | Maintains | Buy |
| 08/15/2023 | 561.76% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 03/16/2023 | 561.76% | HC Wainwright & Co. | → $18 | Reiterates | → Buy |
| 10/26/2022 | 451.47% | Ladenburg Thalmann | → $15 | Initiates Coverage On | → Buy |
| 01/31/2022 | 561.76% | HC Wainwright & Co. | $14 → $18 | Maintains | Buy |
| 10/11/2021 | 414.71% | HC Wainwright & Co. | $9 → $14 | Maintains | Buy |
| 07/15/2019 | 355.88% | HC Wainwright & Co. | $3.5 → $12.4 | Maintains | Buy |
| 12/31/2018 | 28.68% | HC Wainwright & Co. | $8.6 → $3.5 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 10/04/2023 | 1370.59% | HC Wainwright公司 | $18→$40 | 维护 | 买 |
| 2023年08月15日 | 561.76% | HC Wainwright公司 | →$18 | 重申 | 购买→购买 |
| 03/16/2023 | 561.76% | HC Wainwright公司 | →$18 | 重申 | →购买 |
| 10/26/2022 | 451.47% | 拉登堡·塔尔曼 | →$15 | 开始承保 | →购买 |
| 2022年1月31日 | 561.76% | HC Wainwright公司 | $14→$18 | 维护 | 买 |
| 10/11/2021 | 414.71% | HC Wainwright公司 | $9→$14 | 维护 | 买 |
| 2019年07月15日 | 355.88% | HC Wainwright公司 | $3.5→$12.4 | 维护 | 买 |
| 2018年12月31日 | 28.68% | HC Wainwright公司 | $8.6→$3.5 | 维护 | 买 |
What is the target price for Capricor Therapeutics (CAPR)?
Capricor Treateutics(CAPR)的目标价格是多少？
The latest price target for Capricor Therapeutics (NASDAQ: CAPR) was reported by HC Wainwright & Co. on October 4, 2023. The analyst firm set a price target for $40.00 expecting CAPR to rise to within 12 months (a possible 1370.59% upside). 4 analyst firms have reported ratings in the last year.
纳斯达克(纳斯达克代码：CAPR)的最新目标价是由HC Wainwright&Co.于2023年10月4日报道的。这家分析公司将目标价定为40美元，预计CAPR将在12个月内升至(可能上涨1370.59%)。去年有4家分析公司公布了评级。
What is the most recent analyst rating for Capricor Therapeutics (CAPR)?
Capricor Treateutics(CAPR)的最新分析师评级是什么？
The latest analyst rating for Capricor Therapeutics (NASDAQ: CAPR) was provided by HC Wainwright & Co., and Capricor Therapeutics maintained their buy rating.
纳斯达克公司(纳斯达克代码：CAPR)的最新分析师评级由HC Wainwright&Co.提供，Capricor治疗公司维持买入评级。
When is the next analyst rating going to be posted or updated for Capricor Therapeutics (CAPR)?
Capricor Treeutics(CAPR)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Capricor Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Capricor Therapeutics was filed on October 4, 2023 so you should expect the next rating to be made available sometime around October 4, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Capricor Treeutics的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Capricor治疗公司的上一次评级是在2023年10月4日提交的，所以你应该预计下一次评级将在2024年10月4日左右的某个时候提供。
Is the Analyst Rating Capricor Therapeutics (CAPR) correct?
分析师对Capricor Treeutics(CAPR)的评级正确吗？
While ratings are subjective and will change, the latest Capricor Therapeutics (CAPR) rating was a maintained with a price target of $18.00 to $40.00. The current price Capricor Therapeutics (CAPR) is trading at is $2.72, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Capricor Treateutics(CAPR)评级保持不变，目标价在18.00美元至40.00美元之间。Capricor Treateutics(CAPR)目前的交易价格为2.72美元，超出了分析师的预测范围。